End-Payors Again Denied Cert. In Niaspan Pay-For-Delay MDL

By Dave Simpson (August 17, 2021, 9:48 PM EDT) -- A Pennsylvania federal judge once again declined to certify a class of end-payors in their suit alleging improper pay-for-delay settlements between AbbVie and Teva Pharmaceuticals Industries aimed at barring generic forms of cholesterol drug Niaspan, finding Tuesday they again failed to satisfy the ascertainability requirement....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!